High-throughput approaches to discover novel immunomodulatory agents for cancer

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1406-1408

  McMillin, Douglas W ^a   Mitsiades, Constantine S ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; High throughput screening; Immune effector cells; Pharmacological immunomodulators; Tumor heterogeneity

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; IMMUNOMODULATING AGENT; INTERLEUKIN 1; LENALIDOMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; POMALIDOMIDE; THALIDOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER INHIBITION; CELL ACTIVITY; CELL INTERACTION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG INTERACTION; DRUG RESEARCH; DRUG TARGETING; EFFECTOR CELL; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INNATE IMMUNITY; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STROMA; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84886880101     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21058     Document Type: Note

References (10)

1. McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010; 16:483-9; PMID:20228816; http://dx.doi.org/10.1038/nm.2112.
2. McMillin DW, Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, et al. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood 2012; 119:131-8; PMID:22289890; http://dx.doi.org/10.1182/blood-2011-04-348490.
3. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi.org/10.1172/JCI35180.
4. Zitvogel L, Kroemer G. The dilemma of anticancer therapy: tumor-specific versus immune effects. Blood 2008; 112:4364-5; PMID:19029450; http://dx.doi.org/10.1182/blood-2008-09-176693.
5. Zitvogel L, Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J Clin Invest 2009; 119:2127-30; PMID:19620780.
6. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2006; 6:1165-73; PMID:16925483; http://dx.doi.org/10.1586/14737140.6.8.1165.
7. Hideshima T, Richardson PG, Anderson KC. Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs 2006; 15:171-9; PMID:16433596; http://dx.doi. org/10.1517/13543784.15.2.171.
8. De Raeve H, Vanderkerken K. Immunomodulatory drugs as a therapy for multiple myeloma. Curr Pharm Biotechnol 2006; 7:415-21; PMID:17168657; http://dx.doi.org/10.2174/138920106779116847.
9. Shiao SL, Ganesan AP, Rugo HS, Coussens LM. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev 2011; 25:2559-72; PMID:22190457; http://dx.doi.org/10.1101/gad.169029.111.
10. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223.